BioNTech completed the acquisition of AexeRNA Therapeutics for $1bn.

BioNTech, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, completed the acquisition of AexeRNA Therapeutics, a company developing mRNA therapeutics utilizing its proprietary next-generation programmable and highly potent Lipid Nanoparticle nucleic acid delivery system, for $1bn.